Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/62233
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Docobo-Pérez, Fernando | - |
dc.contributor.author | López-Rojas, Rafael | - |
dc.contributor.author | Domínguez-Herrera, Juan | - |
dc.contributor.author | Jiménez-Mejías, M. E. | - |
dc.contributor.author | Pichardo, Cristina | - |
dc.contributor.author | Ibáñez-Martínez, J. | - |
dc.contributor.author | Pachón, Jerónimo | - |
dc.date.accessioned | 2012-12-10T08:29:31Z | - |
dc.date.available | 2012-12-10T08:29:31Z | - |
dc.date.issued | 2012 | - |
dc.identifier | doi: 10.1093/jac/dks142 | - |
dc.identifier | issn: 0305-7453 | - |
dc.identifier.citation | Journal of Antimicrobial Chemotherapy 67(8): 1961-1967 (2012) | - |
dc.identifier.uri | http://hdl.handle.net/10261/62233 | - |
dc.description.abstract | Objectives: The British Thoracic Society, American Thoracic Society and Infectious Diseases Society of America guidelines recommend vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia, based on evidence suggesting that a vancomycin AUC 0-24/MIC ratio of 400 predicts clinical success against MRSA pneumonia. The aim of this study was the evaluation of an optimized dose of vancomycin in the treatment of MRSA experimental pneumonia versus linezolid. | - |
dc.description.abstract | Methods: In vitro activities of vancomycin and linezolid were tested using time-kill curves. Experimental pneumonia in neutropenic C57BL/6 mice was achieved using two clinical MRSA strains, MR30 and MR33 (vancomycin and linezolid MICs of 1 and 4 mg/L, respectively). In vivo dosages were 30 and 110 mg/kg vancomycin (obtaining an AUC 0-24/MIC ratio lower and higher than 400, respectively), and 30 mg/kg linezolid. | - |
dc.description.abstract | Results: Survival rates in controls, and in the groups treated with 120 mg/kg/day vancomycin, 440 mg/kg/day vancomycin and 120 mg/kg/day linezolid were 85.7%, 92.9%, 76.9% and 100%, and 66.7%, 100%, 75% and 100% for MR30 and MR33, respectively. Sterile blood cultures occurred at rates of 21.4%, 64.3%, 100% and 93.8%, and 40%, 66.7%, 100% and 93.3% for MR30 and MR33 strains, respectively. Finally, the respective bacterial lung concentrations (log. 10 cfu/g) were 8.93 ± 0.78, 6.67 ± 3.01, 3.25 ± 1.59 and 2.87 ± 1.86 for MR30, and 8.62 ± 0.72, 5.76 ± 2.43, 3.97 ± 1.52 and 1.59 ± 1.40 for MR33. | - |
dc.description.abstract | Conclusions: These results support that a vancomycin AUC. 0-24/MIC ratio >400 is necessary to obtain a high bacterial lung reduction in MRSA pneumonia, comparable to that achieved with linezolid and better than that with the low dose of vancomycin tested. Linezolid was more efficacious than the pharmacodynamically optimized vancomycin dose in the pneumonia caused by the most virulent strain (MR33). © The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. | - |
dc.description.sponsorship | This work was supported by research grants (113/03) from the Consejería de Salud of the Junta de Andalucia, and by Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III—co-financed by European Development Regional Fund ‘A way to achieve Europe’ ERDF, Spanish Network for Research in Infectious Diseases (REIPI RD06/0008/0000). | - |
dc.language.iso | eng | - |
dc.publisher | Oxford University Press | - |
dc.rights | closedAccess | - |
dc.title | Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant staphylococcus aureus | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1093/jac/dks142 | - |
dc.date.updated | 2012-12-10T08:29:32Z | - |
dc.description.version | Peer Reviewed | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
27
checked on 12-abr-2024
WEB OF SCIENCETM
Citations
24
checked on 26-feb-2024
Page view(s)
377
checked on 18-abr-2024
Download(s)
110
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.